SLC5A2 and chronic kidney disease: A glycated hemoglobin A1c below 7% without hypoglycemia or weight gain, respectively, and treatment with sodium-glucose co-transporters-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are strongly recommended in patients living with type 2 DM for preventing or slowing the progression of CVD or CKD.